- Company
- Will blockbuster contraception Mercilon find a new provider?
- by Nho, Byung Chul Oct 18, 2024 05:49am
- As Alvogen Korea and Chong Kun Dang's co-promotion contracts for oral birth control pills are set to expire, many pharmaceutical·distributors are sending love calls. Sources said that distributors, including pharmaceutical companies with strength in over-the-counter drug sales, have visited Alvogen Korea and Chong Kun Dang to weigh co
- Company
- oHCM drug Camzyos's last hurdle to reimb remains high
- by Eo, Yun-Ho Oct 15, 2024 05:50am
- The reimbursement journey for ‘Camzyos’, which is seeking insurance reimbursement in Korea, is going to be a rocky road until the end. According to industry sources, the drug pricing negotiations between BMS Pharmaceuticals Korea and the National Health Insurance Service (NHIS) for the obstructive hypertrophic cardiomyopathy (oHCM) drug
- Company
- “Market for veterinary drugs expected to grow rapidly”
- by Son, Hyung Min Oct 15, 2024 05:50am
- “MSD Animal Health Korea’s clients are animals. We believe that the drug distribution channels for animals should be carefully designed to contribute to the health of animals in Korea. Supplying our products to animals that need them quickly, sufficiently, and safely is the biggest principle in designing our domestic distribution network.
- Company
- Dong-A ST’s biosimilar first enters the U.S. market
- by Chon, Seung-Hyun Oct 14, 2024 05:49am
- Dong-A S.T. has succeeded in entering the US market 13 years after declaring its entry into the biosimilar business. It has received approval in the US for a biosimilar version of Stelara, which owns a global market worth KRW 14 trillion. It was the company’s second overseas market with a self-developed biosimilar. The biosimilar's entry into t
- Company
- ERT demonstrates effectiveness in treating Fabry disease
- by Whang, byung-woo Oct 11, 2024 06:25am
- "'It has been 20 years since ERT treatments became available for patients with Fabry disease. More treatment options are available to treat Fabry disease, but selecting treatment options and strategy requires precise attention based on research data." Analysis suggests that the treatment environment for rare diseases has improved due to the e
- Company
- ‘Switching between AD drugs’ discussed at NA audit
- by Whang, byung-woo Oct 11, 2024 05:54am
- The issue of switching between medications for severe atopic dermatitis, whose need had been voiced constantly in the clinical field, has been mentioned during the National Assembly Audit, attracting attention to whether the reimbursement environment will change. During the National Audit of the National Assembly's Health and Welfare Co
- Company
- Will Tevimbra be reimbursed promptly in Korea?
- by Eo, Yun-Ho Oct 11, 2024 05:54am
- Whether an immuno-oncology treatment option will arise in the oesophageal cancer space is garnering attention. BeiGene Korea's immuno-oncology drug Tevimbra (tislelizumab) passed the Health Insurance Review and Assessment Service’s Cancer Disease Review Committee in August during its second attempt. Tevimbra is a PD-1 inhibiting immuno-o
- Company
- SK bioscience invests KRW 4.1B stake in a U.S. biotech
- by Kim, Jin-Gu Oct 10, 2024 05:51am
- SK bioscience announced on October 8th that the company has signed an agreement to acquire a stake in U.S. biotech Fina Biosolutions by investing USD 3 million (approximately KRW 4.1 billion). SK bioscience became the first and only strategic investor of Fina Biosolutions. According to the contract between both companies, the specific stake
- Company
- Who will distribute Mounjaro in Korea?
- by Whang, byung-woo Oct 10, 2024 05:50am
- As Novo Nordisk's obesity drug Wegovy (semaglutide) is set to be released, the industry’s interest is on which domestic distributor Lilly will choose for its Mounjaro (tirzepatide). According to industry sources on the 8th, Boryung Pharmaceutical and Chong Kun Dang are in the running to become domestic distributors of Wegovy’s rival ob
- Company
- Wegovy's release on the 15th…competitor Mounjaro
- by Whang, byung-woo Oct 8, 2024 05:49am
- With the release of Wegovy, the next-generation obesity drug, set for the middle of this month (October), the release of its competitor Mounjaro is also gaining attention. Although Lilly has not yet announced a specific launch date for its Mounjaro, the company has opted to add another indication to its drug rather than apply for new drug app
